Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CFO Paul J. Mellett Sells 10,440 Shares

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) CFO Paul J. Mellett sold 10,440 shares of the firm’s stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $44.43, for a total value of $463,849.20. Following the sale, the chief financial officer now directly owns 97,556 shares of the company’s stock, valued at $4,334,413.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $42.09 on Friday. The stock’s 50 day moving average price is $49.47 and its 200 day moving average price is $48.90. Enanta Pharmaceuticals, Inc. has a 52 week low of $37.59 and a 52 week high of $79.50. The company has a market capitalization of $879.26 million, a P/E ratio of -7.23 and a beta of 0.40.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last released its quarterly earnings data on Tuesday, February 7th. The biotechnology company reported ($1.39) EPS for the quarter, topping analysts’ consensus estimates of ($1.52) by $0.13. Enanta Pharmaceuticals had a negative return on equity of 36.59% and a negative net margin of 146.93%. The firm had revenue of $23.60 million for the quarter, compared to the consensus estimate of $22.48 million. During the same quarter in the prior year, the company posted ($1.48) earnings per share. The firm’s revenue was down 14.5% on a year-over-year basis. As a group, sell-side analysts forecast that Enanta Pharmaceuticals, Inc. will post -7.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ENTA. State Street Corp increased its holdings in Enanta Pharmaceuticals by 29.9% in the second quarter. State Street Corp now owns 1,699,428 shares of the biotechnology company’s stock worth $80,332,000 after buying an additional 390,842 shares during the last quarter. Braidwell LP acquired a new position in Enanta Pharmaceuticals during the fourth quarter valued at approximately $15,158,000. Norges Bank acquired a new position in Enanta Pharmaceuticals during the fourth quarter valued at approximately $10,533,000. JPMorgan Chase & Co. grew its holdings in Enanta Pharmaceuticals by 349.1% during the second quarter. JPMorgan Chase & Co. now owns 177,654 shares of the biotechnology company’s stock valued at $8,398,000 after purchasing an additional 138,097 shares during the last quarter. Finally, FMR LLC grew its holdings in Enanta Pharmaceuticals by 44.7% during the second quarter. FMR LLC now owns 350,333 shares of the biotechnology company’s stock valued at $16,560,000 after purchasing an additional 108,161 shares during the last quarter. Institutional investors and hedge funds own 93.68% of the company’s stock.

Analysts Set New Price Targets

ENTA has been the subject of several recent analyst reports. JMP Securities reaffirmed a “buy” rating and issued a $96.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 22nd. Royal Bank of Canada decreased their target price on Enanta Pharmaceuticals from $65.00 to $54.00 and set a “sector perform” rating for the company in a research report on Tuesday, November 22nd. HC Wainwright raised their target price on Enanta Pharmaceuticals from $56.00 to $68.00 in a research report on Wednesday, February 8th. StockNews.com initiated coverage on Enanta Pharmaceuticals in a research report on Thursday. They issued a “hold” rating for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $87.00 target price on shares of Enanta Pharmaceuticals in a research report on Wednesday, February 8th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $68.60.

About Enanta Pharmaceuticals

(Get Rating)

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.